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Abstract
Background: Thyroid receptors, TRα and TRβ, are involved in important physiological functions
such as metabolism, cholesterol level and heart activities. Whereas metabolism increase and
cholesterol level lowering could be achieved by TRβ isoform activation, TRα activation affects
heart rates. Therefore, β-selective thyromimetics have been developed as promising drug-
candidates for treatment of obesity and elevated cholesterol level. GC-1 [3,5-dimethyl-4-(4'-
hydroxy-3'-isopropylbenzyl)-phenoxy acetic acid] has ability to lower LDL cholesterol with 600- to
1400-fold more potency and approximately two- to threefold more efficacy than atorvastatin
(Lipitor©) in studies in rats, mice and monkeys.
Results: To investigate GC-1 specificity, we solved crystal structures and performed molecular
dynamics simulations of both isoforms complexed with GC-1. Crystal structures reveal that, in
TRα Arg228 is observed in multiple conformations, an effect triggered by the differences in the
interactions between GC-1 and Ser277 or the corresponding asparagine (Asn331) of TRβ. The
corresponding Arg282 of TRβ is observed in only one single stable conformation, interacting
effectively with the ligand. Molecular dynamics support this model: our simulations show that the
multiple conformations can be observed for the Arg228 in TRα, in which the ligand interacts either
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BMC Structural Biology 2008, 8:8 http://www.biomedcentral.com/1472-6807/8/8strongly with the ligand or with the Ser277 residue. In contrast, a single stable Arg282
conformation is observed for TRβ, in which it strongly interacts with both GC-1 and the Asn331.
Conclusion: Our analysis suggests that the key factors for GC-1 selectivity are the presence of an
oxyacetic acid ester oxygen and the absence of the amino group relative to T3. These results shed
light into the β-selectivity of GC-1 and may assist the development of new compounds with
potential as drug candidates to the treatment of hypercholesterolemia and obesity.
Background
Thyroid hormones (TH) have important roles in develop-
ment and homeostasis. Thyroid receptor (TR) activation
occurs when an agonist ligand such as TH or similar com-
pounds binds to a hydrophobic pocket in the core of its
ligand-binding domain (LBD). This causes conforma-
tional changes which allow DNA bound receptors to
interact with coactivators, mediating transcription. TH has
a considerable potency as a cholesterol reducer in serum,
and stimulates basal metabolic rate, promoting weight
loss by the increase of thermogenesis [1,2]. However, del-
eterious side effects such as tachycardia and atrial arrhyth-
mia are well-documented rendering TH treatment
unviable for the treatment of obesity and hypercholester-
olemia [3-8].
While TH cannot be used to treat dyslipidemias and obes-
ity, TR isoform selective agonists may counteract these
problems. The human (h) TR exists in two isoforms, hTRα
(NR1A1), and hTRβ (NR1A2). hTRα is expressed at higher
levels in heart and plays a major role in regulation of heart
rate, whereas TRβ is the predominant isoform that is
expressed in the liver and pituitary and is involved with
hepatic cholesterol metabolism and regulation of meta-
bolic rate [9,10]. Evidence from human patients and
mouse models suggests that elevated cholesterol and body
weight can be decreased by the preferential activation of
hTRβ versus hTRα. Since obesity and atherosclerosis are
important medical problems with impact on morbidity
and mortality, development of β-selective thyromimetics
and improved understanding of their actions is an impor-
tant pharmacological and biomedical issue.
Similar to other nuclear receptors, TRs exhibit a modular
structure, composed of functionally separable domains.
The most highly conserved domains are the LBD and
DNA binding domain (DBD), with the former responsi-
ble for multiple activities, including hormone binding,
homo and/or heterodimerization, molecular interactions
with heat-shock-proteins, and transcriptional activation
and repression [11-14]. All of these properties are regu-
lated by ligand-dependent conformational changes
[13,14]. Therefore, improved understanding of the three-
dimensional structure of a liganded LBD and dynamic
changes that occur on ligand binding are critical for
understanding hormone action. While hTRβ LBD crystal
structures of complexes with natural hormones (T3, thy-
roxine T4, TRIAC) and synthetic ligands (among them GC-
1, GC-24, KB-141) are available, structural information
on hTRα LBD is scarce [15-19]. Even less information
about the role of TR flexibility and dynamics in ligand
binding is available. For example, it was only recognized
recently that TR ligands dissociation (and, presumably,
association) can proceed via multiple escape pathways
that may be ligand specific [20,21].
GC-1 (3,5-Dimethyl-4-(4'-hydroxy-3'-isopropylbenzyl)-
phenoxy acetic acid; Fig. 1), is an analogue of the thyromi-
metic DIMIT that shows comparable affinity for hTRβ1 to
T3 and desirable isoform selectivity, binding to hTRα1
with a 10-fold lower affinity [22,23]. GC-1 shows
extremely encouraging results in animal models [24-31].
GC-1 lowers cholesterol in hypothyroid mice and mon-
keys at concentrations that do not affect heart rate and
lowers LDL cholesterol with 600- to 1400-fold more
potency and approximately two- to threefold more effi-
cacy than atorvastatin (Lipitor©)[24,28,29]. GC-1 also
decreases plasma levels of other atherogenic lipids; triglyc-
erides and lipoprotein (a). Further, GC-1 induces loss of
body fat with no detectable loss of muscle [28,29].
Finally, GC-1 stimulates important steps in reverse choles-
terol transport [31]. GC-1 is also a synthetically accessible
scaffold that serves as a platform for the development of
new TR agonists and antagonists [32-34]. Thus, improved
understanding of the structural basis of GC-1 TR binding
and selectivity is of paramount importance for the
rational design of thyromimetics.
Presently, only an X-ray structure of TRβ in complex with
GC-1 is available. While this structure reveals extensive
hydrogen bond formation between the carboxylate tail of
the ligand and polar residues in the hormone binding
pocket, improved understanding of the molecular basis of
isoform-selective binding awaits direct comparisons of
structures of both TR isoforms in complex with this ligand
[16]. Here, we report the new structures of hTRα and hTRβ
LBDs in complex with GC-1 and T3 and results of MD sim-
ulations performed with these structural models. Our data
suggests that most of the selective binding of GC-1 is
related to alternate conformations of a conserved Arg res-
idue in the pocket (Arg228α/Arg282β) that, in turn, isPage 2 of 13
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with the single isoform-selective residue in the pocket.
Results
X-ray structures
Cell-based assays confirmed that our preparation of GC-1
(Materials and Methods) has potent TR agonist activity,
with maximum efficacy similar to that of T3 and selectivity
for TRβ vs. TRα (Additional file 1, Fig. 1S). Co-crystalliza-
tion of GC-1 with both hTRα and hTRβ yielded structures
with good geometric and crystallographic parameters
(Table 1). The Ramachandran plots are acceptable for
both structures. These plots assess the main chain config-
uration of a protein by a 2D graph displaying the two tor-
sional angles (ϕ and ψ) of each amino acid residue, which
should be clustered in regions that don't cause steric
clashes between them. No residues were observed in the
disallowed regions of the plots, except for Arg188 in TRα
structure in P212121. Electron density for the ligand was
clear and well-defined in all the structures obtained.
Ligand binding pocket
The TR ligand binding pocket is roughly subdivided in
three regions, as shown in Figure 2. Region I is largely
hydrophobic but contains a single polar residue
(His435β/381α) which forms a hydrogen bond interac-
tion with a hydroxyl group of most thyromimetics or thy-
roid hormones, including T3, T4 and TRIAC. TH analogues
synthesized without the phenol on that position tend to
lack functionality [18]. Region II is mainly composed of
apolar residues that interact with the thyronine rings of
TH derivatives or phenolic rings of thyromimetics such as
GC-1. Region III, occupied by the oxyacetic acid moiety of
GC-1, is mostly polar and is the likely location in which
changes in interaction with T3 and GC-1 determine the
selectivity of the compound because it harbours the only
subtype selective residue in the hTRα and hTRβ binding
pockets; hTRα has a Ser 277 residue, which is substituted
by Asn 331 in hTRβ. GC-1 carboxyl group interactions are
mostly mediated by three arginine residues (Arg228,
Arg262 and Arg266 in hTRα) through water molecules
supported hydrogen bonding network.
Comparison of hTRα and hTRβ complexed with T3 con-
firms that there is a similar binding mode [35,36]. The
hormone binds both receptors in the extended conforma-
tion forming the same interactions with the amino acid
residues of the active sites (Fig. 3a). The lack of structural
differences is consistent with the fact that T3 binds both TR
isoforms with similar affinity.
Table 1: Crystallographic information
hTRα + GC-1 (first crystal form) hTRα + GC-1 (second crystal 
form)
hTRα + T3 hTRβ + GC-1 hTRβ + T3
Space group P212121 C2 P212121 P3121 P3121
Cell Parameters (Å) a = 59.91
b = 80.35
c = 102.89
a = 89.80
b = 78.78
c = 43.07
β = 95.18
a = 59.98
b = 80.79
c = 102.21
a = 68.99
b = 68.99
c = 130.86
a = 68.95
b = 68.95
c = 131.11
Resolution (Å) 43.44 – 1.85 58.72 – 2.50 63.25 – 1.87 33.35 – 2.55 33.35 – 2.30
I/(σ) 35.81 (3.64) 7.8 (2.1) 7.8 (2.0) 17.66(2.31) 25.75(2.02)
Total number of reflections 40931 9551 39069 11291 15596
Completeness (%) 100 91.7 (83.7) 98.7 (98.9) 96.9(99.0) 99.0
Multiplicity 6.3 (6.0) 7.2 (7.2) 8.2 (7.8) 3.9 (3.7) 16.1 (5.5)
Rmergea (%) 4.3 (49.2) 7.6 (36.6) 5.9 (38.3) 6.7 (57.7) 7.7 (56.5)
Bond length (Å) 0.037 0.018 0.041 0.033 0.024
Bond angles (deg) 3.047 1.813 3.846 3.082 2.631
Rfactor (%) 14.9 18.8 14.8 20.3 20.4
Rfree (%) 18.8 26.3 18.6 27.6 25.4
Bleicher1.pngFigur  
Bleicher1.png. Chemical formulas of GC-1 (a) and T3 (b).Page 3 of 13
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ent. Similar to T3, GC-1 binds both TRs through a combi-
nation of hydrophobic interactions and two hydrogen
bond sites. The first hydrogen bond involves the phenolic
hydroxyl of the outer thyronine ring and a histidine resi-
due in region I of the pocket (His381/435). The second
site involves the GC-1 oxyacetic acid substituent and the
positively charged pocket formed by three arginine resi-
dues in region III, Arg228/282, Arg262/316 and Arg266/
320 (Fig. 3b and 3c). In hTRβ, Arg282 from helix 3, and
Arg316 and Arg320 from helix 6 interact with the GC-1
oxyacetic acid carboxylate both directly and via water-
mediated hydrogen bond interactions, as previously
observed in a previous hTRβ/GC-1 structure [16]. Asn331
forms a hydrogen bond with Arg282 that anchors the lat-
ter in place and permits it to form a stable interaction with
the GC-1 carboxylate group.
In hTRα, a different picture arises. First, the GC-1 oxyace-
tic acid ester oxygen forms a hydrogen bond with the
main chain amino group of TRα specific Ser277 residue.
The Ser277 side chain hydroxyl participates in a hydrogen
bond interaction with the Ile221 main chain carbonyl
group, which is not available to Asn331 in hTRβ. This
means that Ser277 fails to engage in a hydrogen bond
contact with Arg228 analogous to that observed between
Asn331 and Arg282. Thus, Arg228 is not anchored by con-
tacts with the subtype specific residue. In addition, Ser277
is displaced by 1.64 Å toward the ligand compared to the
T3-bound hTRα[36]. This effect, coupled with the fact that
dislocation and the smaller size of Ser relative to Asp in
TRβ provides room for the Arg228 side chain to move,
permits Arg228 to adopt apparent multiple conforma-
tions, as described below.
To distinguish between the conformations of the Arg228
side chain, we will call the first, similar to the TRβ +GC-1
structure, the productive conformation, and the two alterna-
tives, the non-productive conformations. Arg228 displays a
double conformation in the first hTRα crystal form
(P212121, Table 1): a productive conformation identical to
that of hTRβ and a non-productive conformation in
which it points away from ligand (Fig. 3a, in green). In the
second crystal form (C2 space group, Table 1) Arg 228 is
in another non-productive conformation (Fig. 3a, in
white) which is an intermediate between two conforma-
tions of the same residue found in the first crystal form.
Differential positioning of the Arg228 side chain is related
to hydrogen bond with the Ser277 carbonyl group that
flips the Arg228 side chain into an alternative conforma-
tion (Fig. 3c). To compensate this conformational change,
a water molecule (W343) bridges the Arg228 side chain
and the GC-1 carboxylate group. This weakens direct
interaction with Arg228 and forces GC-1 into a new con-
formation which involves re-orientation of its carboxyl
group.
Thus, our structures reveal different binding modes for
GC-1 in TRα and TRβ. In TRβ a single productive confor-
mation is observed, in which the ligand interacts strongly
with Arg282, while this residue interacts with the carbonyl
group of Asn331. In TRα, multiple conformations are
observed. In the productive conformation the ligand
interacts strongly with the Arg228 residue and with the
Bleicher2.pngFigur  
Bleicher2.png. The TR hormone binding site, shown as T3 bound to hTRβ. The regions shown in red, gray and blue corre-
spond to regions I, II and III described in the text. Apolar residues are shown in gray, basic residues in blue (namely His435, 
Arg316, Arg282 and Arg320) and polar residues in orange (including Asn331).Page 4 of 13
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Bleicher3.pngFigur  
Bleicher3.png. Ligand-receptor interactions for thyroid receptors: (a) T3 as bound to hTRα (green) and hTRβ (magenta). All 
interactions are maintained between the ligand and the binding site residues in both hTR isoforms. Both Ser277 and Asn331 
interact with the amino group of T3 through their amide nitrogen, leading to similar conformations of these residues. (b) GC1 
bound to TRα: multiple conformations of the Arg228 are observed. In the productive conformation there is a strong interac-
tion with the ligand (cyan), while in non-productive conformations this residue interacts with the side-chain of Ser277. The 
Arg228 double conformation is observed in the first crystal form of hTRα LBD+GC1 complex (Table 1). In the intermediate 
conformation Arg228 interacts both with the GC1 and the Ser277 amino group (white, second hTRα LBD+GC-1 crystal form, 
Table 1). (c) Comparison of GC1 bound to hTRα and hTRβ. For hTRβ (magenta) only a single productive conformation of the 
Arg282 side-chain was observed, which resembles the productive Arg228 (hTRα) conformation (green). Arg282 (hTRβ), is 
strongly interacting with the ligand and its productive conformation is locked in place by the interactions with the side-chain of 
Asn331.
BMC Structural Biology 2008, 8:8 http://www.biomedcentral.com/1472-6807/8/8Ser277 by its oxyacetic oxygen. In the non-productive con-
formations GC-1 maintains the interaction with Ser277
but the strong interaction of GC-1 with Arg228 is lost, giv-
ing way to a hydrogen bond of this residue with the main
carbonyl of Ser277.
Molecular dynamics simulations
Conformational variability of the Arg228 residue in TRα
was also observed in MD simulations (Fig. 4). For hTRβ
the residue oscillates around a mean defined value, indi-
cating a single conformation. In hTRα, the RMSD of the
Arg228 side-chain has much larger flexibility, as shown in
Figure 4(a). This is a result of the weaker anchoring it dis-
plays relative to the Arg282 of TRβ that interacts both with
the ligand and with the Asn331 residue. This weak
anchoring of the Arg228 residue allows for multiple bind-
ing modes, which are characterized by basically two differ-
ent distances between the carboxylate of GC1 and Arg228,
that can be seen in Figure 4(b). Overlaps of snapshots of
the simulations at different times in Figure 4(c) and 4(d)
illustrate the conformations and the binding modes
observed.
To understand whether the apparent instability of the GC-
1-Arg228α explains weaker ligand binding to this receptor
isoform, we analyzed the energies of these interactions
obtained from the molecular dynamics simulations. Fig-
ure 5 shows a schematic representation of the binding
modes of GC-1 in hTRα and hTRβ, together with the aver-
age energies of each interaction as computed by MD sim-
ulations. In the productive conformations of GC-1 bound
both to hTRα and hTRβ there is a strong (-90 kcal/mol)
interaction between the GC-1 carboxylate and Arg228/
282. The second strongest interaction is the hydrogen
bond that Arg282 forms with the Asn331 residue in the
hTRβ isoform (-19 kcal/mol). The corresponding Arg228-
Ser277 interaction is comparatively weak (-8 kcal/mol).
In the non-productive conformation observed in hTRα,
the GC-1-Arg228 interaction is weakened to -54 kcal/mol.
This conformational change is accompanied by the
entrance of a water molecule that forms a hydrogen bond
with the carboxylate of GC-1. Also relevant is the fact that
the Arg228 residue in the non-productive conformations
strengthens its interaction with Ser277 (from -8 to -13
kcal/mol). The Ser277-Ile221 interaction does not appear
to be particularly relevant. The hydrogen bond of GC-1
with the Ser277 is quite strong (-11 kcal/mol), and some-
what favours binding to hTRα relative to hTRβ. A slight
rearrangement of the hydrophobic residues in the binding
site is also observed, but the differences in interaction
energies are negligible (< 1 kcal/mol).
Together, these data suggest a plausible explanation for
the greater affinity of GC-1 for the hTRβ isoform. The pro-
ductive conformations of the Arg228/282 residues are the
driving forces leading to ligand binding stabilization. Very
strong interactions of these residues with GC-1 appear in
productive conformations of both TR-isoforms. The rea-
son for the productive conformation to be more stable in
hTRβ than in hTRα is related to the differences in the side-
chains of the Ser277 and Asn331 residues. In hTRβ,
Arg282 interacts, at the same time, with the carboxylate of
the ligand and with the side chain of Asn331, which locks
in place the productive conformation of the former resi-
due. In hTRα, Arg228 has the potential to engage in strong
charge-charge interactions with the ligand, but the short
side-chain of Ser277 residue is unable to lock it in place.
Therefore, the stabilization of the productive conforma-
tion resulting from the Arg282-Asn331 interaction is of
key importance for hTRβ selectivity of GC-1.
Specific Binding of GC-1 is related to the Absence of the 
Amino Group
Why is this isoform-specific binding mode available to
GC-1 and not T3? T3 contains an amino group that is miss-
ing from GC-1 and it is known that removal of the amino
group in both T3 and GC-1 analogues improves β-selectiv-
ity. For T3, the removal of the amino group results in a
slightly β-selective ligand [17]. For GC-1 analogues it
turns the DIMIT ligand (1.6 times selective) into the pro-
pionic-acid GC-1, which is 4.5 times selective towards
TRβ22. Superposition of structures of T3 and GC-1 bound
to both TR isoforms reveals significant movement of the
part of the TR polypeptide backbone containing the
Ser277 and Asn331 residues in the GC-1 structures (Fig.
6), that is a result of the absence of the T3 amino-Ser277/
Asn331 interactions. This movement allows the Ser277
and Arg331 residues to interact with other residues of the
binding pocket (Ile221 with Ser277 and Arg282 with
Arg331) in the presence of GC-1. Hence, removal of the T3
amino group allows for the displacement of the chains
containing the Ser277 and Asn331 residues and resulting
difference in binding modes; as described above, the
Asn331-Arg282 (hTRβ) interaction stabilizes the produc-
tive conformation, while the Ser277-Ile221 (hTRα) inter-
action has no effect on ligand affinity.
Discussion
We have presented a structural investigation of ligand
binding modes of the two isoforms of human TR with T3
and GC-1 and a computational analysis of the interaction
energies involved in these systems. Our findings suggest
that the basis of GC-1 selectivity lies in the differences in
ligand and protein conformations, which are related to
the absence of the amino group relative to T3 and to the
Ser/Asn active-site substitution. This substitution
increases the space available to a conserved Arg residue
(Arg228) permitting it to adopt multiple conformations
that are indicative of increased flexibility. While hTRβ
Arg282 binds to the ligand in a single conformation,Page 6 of 13
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Bleicher4.pngFigur  
Bleicher4.png. Conformational variability of the Arg228 (hTRα) and Arg282 (hTRβ) residues as observed from molecular 
dynamics simulations. (a) The greater flexibility of the Arg228 side chain relative to the Arg282 side chain can be observed by 
the larger RMS deviations. This flexiblity results from weaker anchoring of this side chain in hTRα. (b) Two binding modes can 
be distinguished if one computes the CZ-C20 distance. (c) The snapshots of Arg282 show practically the same productive con-
formation, locked in place by the strong interaction with the Asn331 side-chain. (d) Asn331 (hTRβ) to Ser277 (hTRα) substitu-
tion removes these conformational restrains and allows Arg228 to sample a much wider range of conformations. The non-
productive conformations encountered in the simulations resemble closely the non-productive conformations of Arg228 found 
in the crystallographic structures.
Bleicher5.pngFigur  
Bleicher5.png. Average interaction energies involved in the binding of GC-1 to TRα and TRβ as computed from molecular 
dynamics simulations.
BMC Structural Biology 2008, 8:8 http://www.biomedcentral.com/1472-6807/8/8hTRα Arg228 has the potential to flip away from the lig-
and in non-productive conformations, resulting in loss of
an important interaction for the stabilization the ligand.
Our model is supported by MD simulations. The simula-
tions reveal that, for GC-1 bound hTRα, Arg228 can
assume multiple conformations, and although GC-1 has
the additional interaction with Ser277, the overall bind-
ing energy of hTRα is smaller. On the other hand, the pro-
ductive conformation of Arg282 with GC-1 in hTRβ is
very stable both in X-ray structure and in MD simulations,
being locked in place by the strong interaction of the side-
chain of Asn331.
Conclusion
The x-ray structures of both thyroid hormone receptor iso-
forms as bound to GC-1 and to natural hormone T3 per-
mitted the proposal of a β-selectivity mechanism for GC-
1, which is supported by molecular dynamics simulations
of the complexes.
The major contributions for selectivity in GC-1 are the
presence of an oxyacetic acid ester oxygen and the absence
of the amino group relative to T3. These features favour
different conformations for residues in the binding site
which, as described, modify the binding network of the
ligand for the two isoforms.
In summary, our analysis sheds light into the molecular
basis of TRβ-selectivity of GC-1 and may assist rational
design of new TH analogs with improved TRβ selectivity
lacking the undesirable properties of the natural hor-
mones.
Methods
Synthesis of GC-1
GC-1 (compound 7) was synthesized from commercial
starting materials by the convergent synthetic route (Addi-
tional file 1, Fig. 2S), as described previously by Chiellini
et al. [37].
The bromo-ether 1, prepared from the commercial 4-
bromo-2-isopropylphenol, was reacted with the protected
Bleicher6.pngFigur  
Bleicher6.png. Superposition of the crystal structures of T3 (blue and sky blue) and GC1 (red and orange) bound to two hTR 
isoforms highlights the conformational variability associated with the Ser277 and Asn331 residues. This variability is mostly a 
result of the lack of the amine group in GC-1, but its presence in T3.Page 8 of 13
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dimethylphenol, to produce the biaryl alcohol 4. Hydrog-
enolysis of alcohol 4 gives the diether 5, which was treated
with TBAF (tetra-n-butylammonium fluoride) to provide
the selective removal of the phenolic silyl ether proteting
group, furnishing the free phenol 6. Alkylation of 6 with
bromoacetic acid, followed by removal of the meth-
oxymethyl phenolic protecting group under acid condi-
tions, produced the target compound GC-1 (7), in 39%
overall yield.
4-Bromo-2-isopropyl phenyl methoxymethyl ether (1)
Monochloromethylether (1.55 mL, 19.2 mol) was added
dropwise to a solution of 4-bromo-2-isopropylphenol
(2.10 g, 9.62 mmol) and diisopropylamine (3.35 mL,
19.3 mmol) in THF (10 mL) under inert atmosphere and
stirred at room temperature during 30 min. The reaction
mixture was diluted with 30 mL of water and extracted
with dichloromethane (4 × 5 mL). The organic layer was
dried over anhydrous MgSO4, filtered, and evaporated
under reduced pressure to give an oil, which was purified
by column chromatography through silica gel, using n-
hexane:ethyl acetate (95:5) as eluent, to give the pure
product 1 (2.20 g, 8.50 mmol, 88%). 1H NMR (CDCl3,
400 MHz) δ 1,20 (d, 6H, J = 6,9 Hz), 3,31 (heptet, 1H, J =
7,1 Hz), 3,51 (s, 3H), 5,20 (s, 2H), 6,95 (d, 1H, J = 8,7
Hz), 7,22 (dd, 1H, J = 8,7 and 3.1 Hz), 7,40 (d, 1H, J = 3,1
Hz); 13C NMR (CDCl3, 100 MHz) δ 22.7, 27.0, 56.1, 95.0,
114.5, 116.1, 129.8, 140.1, 154.5.
O-Triisopropylsilyl-4-bromo-3,5-dimethylphenol (2)
A solution of 4-bromo-3,5-dimethylphenol (1.50 g, 7.45
mmol), imidazole (1.26 g, 16.3 mmol) and triisopropyls-
ilyl chloride (1.36 g, 7.1 mmol) in dichloromethane (30
mL) was stirred for 1 h at room temperature. The reaction
mixture was diluted with dichloromethane (20 mL),
washed with water (10 mL), brine (10 mL), dried over
anhydrous MgSO4, filtered and evaporated to give an oil,
which was purified by column chromatography through
silica gel, using n-hexane:ethyl acetate (90:10) as eluent,
to furnish compound 2 (1.95 g, 6.70 mmol, 89%) as an
oil. 1H NMR (CDCl3, 400 MHz) δ 1.15 (d, 18H, J = 6.9
Hz), 1.26 (m, 3H), 2.35 (s, 6H), 6.60 (s, 2H); 13C NMR
(CDCl3, 100 MHz) δ 12.5, 17.5, 23.5, 117.1, 119.3, 138.5,
155.6.
2,6-Dimethyl-4-O-triisopropylsilylbenzaldehyde (3)
To a solution of 2 (2.00 g, 5.6. mmol) in tetrahydrofuran
(10 mL) at -78°C under inert atmosphere was added of n-
butyllithium (3.0 mL, 2.0 M in pentane). The reaction
mixture was stirred for 30 min at -78°C and then DMF
(0.82 g, 11.2 mmol) was added. The reaction mixture was
stirred for 1 h at -78°C and for 1 h at room temperature,
diluted with ethyl ether (10 mL), washed with 10 mL of
water acidified with 1 M HCl, and brine (5 × 10 mL). The
organic layer was dried over anhydrous MgSO4, filtered,
and evaporated to give the crude product, which was puri-
fied by column chromatography through silica gel, using
n-hexane:ethyl acetate (90:10) as eluent, to produce 3
(1.20 g, 3.93 mmol, 70%) as a clear oil. 1H NMR (CDCl3,
400 MHz) δ 1.12 (d, 18H, J = 6.9 Hz), 1.25 (m, 3H), 2.55
(s, 6H), 6.55 (s, 2H), 10.50 (s, 1H); 13C NMR (CDCl3, 100
MHz) δ 12.5, 17.6, 20.7, 119.3, 120.5, 144.5, 159.6,
191.5.
3,5-Dimethyl-4-(3'-isopropyl-4'-O-
methoxymethylbenzylhydroxy)-O-triisopropylsilylphenol 
(4)
n-butyllithium (2,90 mL, 2.0 M in pentane) was added to
a solution of 1 (1.00 g, 3.8 mmol) in tetrahydrofuran (10
mL) at -78°C under inert atmosphere. The reaction mix-
ture was stirred for 30 min at -78°C and then aldehyde 3
(1.18 g, 3.9 mmol) in tetrahydrofuran (10 mL) was
added. The mixture was stirred for 1 h at -78°C and for 6
h at room temperature. After that, the reaction mixture
was diluted with ethyl ether (10 mL), washed with 20 mL
of water acidified with 1 M HCl, and brine (5 × 10 mL).
The organic layer was dried over anhydrous MgSO4, fil-
tered, and evaporated to give the crude product, which
was purified by chromatography through silica gel, using
n-hexane:ethyl acetate (90:10) as eluent, to yield 4 (1.07
g, 2.15 mmol, 57%) as an oil. 1H NMR (CDCl3, 400 MHz)
δ 1.10 (d, 18H, J = 6.9 Hz), 1.20 (dd, 6H, J = 6.6, 6.9 Hz),
1.25 (m, 3H), 2.24 (s, 6H), 3.35 (heptet, 1H, J = 6.9 Hz),
3.51 (s, 3H), 5.22 (s, 2H), 6.25 (s, 1H), 6.62 (s, 2H), 6.98
(m, 2H), 7.20 (s, 1H); 13C NMR (CDCl3, 300 MHz) δ
12.5, 17.5, 20.6, 22.5, 27.0, 31.5, 56.0, 71.0, 94.5, 113.5,
120.0 123.5, 132.0, 136.1, 137.0, 138.2, 153.0, 155.0.
3,5-Dimethyl-4-(3'-isopropyl-4'-O-
methoxymethylbenzyl)-O-triisopropylsilylphenol (5)
A solution of 4 (0.73 g, 1.50 mmol) in methanol (5 mL)
was hydrogenated using 10% palladium on activated car-
bon powder (50 mg) under 2 atm of hydrogen at room
temperature. After 12 h of reaction, the catalyst was
removed by filtration and the solvent was evaporated
under reduced pressure, to furnish the crude compound 5
(0.565 g, 1.2 mmol) as an oil, that was used in the next
step without further purification. 1H NMR (CDCl3, 400
MHz) δ 1.10 (d, 18H, J = 6.9 Hz), 1.20 (d, 6H, J = 6.9 Hz),
1.30 (m, 3H), 2.15 (s, 6H), 3.30 (heptet, 1H, J = 6.9 Hz),
3.50 (s, 3H), 3.90 (s, 2H), 5.15 (s, 2H), 6.60 (s, 2H), 6.67
(dd, 1H, J = 2.4 Hz, 8.4 Hz), 6.90 (m, 2H); 13C NMR
(CDCl3, 100 MHz) δ 12.5, 17.0, 20.5, 22.8, 27.0, 33.8,
56.0, 95.0, 114.0, 119.5, 125.5, 130.0, 133.5, 137.5,
138.0, 152.5, 154.0.Page 9 of 13
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phenol (6)
The crude compound 5 (0.40 g, 0.85 mmol) and tetra-n-
butyl-ammonium fluoride (1.06 mmol, 1.0 M in tetrahy-
drofuran) were stirred to provide the selective removal of
the silyl proteting group. After 10 min, the reaction mix-
ture was diluted with ethyl acetate (10 mL) and washed
with brine (3 × 5 mL), dried over anhydrous MgSO4, fil-
tered, and concentrated. The crude product was purified
by column chromatography through silica gel, using n-
hexane:ethyl acetate (80:20) as eluent, to yield 6 (0.25 g,
0.79 mmol, 93% from 4); 1H NMR (CDCl3, 400 MHz) δ
1.20 (d, 6H, J = 6.9 Hz), 2.15 (s, 6H), 3.30 (heptet, 1H, J
= 6.9 Hz), 3.48 (s, 3H), 3.91 (s, 2H), 5.15 (s, 2H), 6.60 (s,
2H), 6.67 (dd, 1H, J = 2.4, 8.4 Hz), 6.90 (d, 1H, J = 8.4
Hz), 6.95 (d, 1H, J = 2.4 Hz); 13C NMR (CDCl3, 100 MHz)
δ 20.5, 23.0, 27.2, 34.0, 56.5, 95.0, 114.5, 115.0, 125.5,
126.0, 130.0, 133.5, 137.5, 139.0, 153.5.
GC-1 [3,5-Dimethyl-4-(4'-hydroxy-3'-isopropylbenzyl) 
phenoxy] acetic acid (7)
To a slurry of NaH (0.049 g, 1.02 mmol) in tetrahydro-
furan (10 mL) at reflux was added compound 6 (0.25 g,
0.79 mmol) and after 30 min a solution of bromoacetic
acid (0.074 g, 053 mmol) in tetrahydrofuran (10 mL).
The reaction mixture was stirred for 4 h at reflux, poured
into 2 mL of cold 1 M HCl, and extracted with ethyl ace-
tate (3 × 10 mL). The combined organic portions were
dried over anhydrous MgSO4, filtrated, and evaporated.
The residue was diluted with methanol (10 mL) and 3
drops of 6 M HCl was added. The reaction mixture was
stirring for 24 h at room temperature, and the solvent was
evaporated. The crude product was purified by column
chromatography through silica gel, using n-hexane:ethyl
acetate (90:10) as eluent, to yield GC-1 (0.19 g, 0.58
mmol, 73%). 1H NMR (CDCl3, 400 MHz) δ 1.15 (d, 6H,
J = 7.1 Hz), 2.15 (s, 6H), 3.10 (heptet, 1H, J = 6.8 Hz),
3.86 (s, 2H), 4.60 (s, 2H), 6.49–6.62 (m, 2H), 6.65 (s,
2H), 6.85 (s, 1H); 13C NMR (CDCl3, 100 MHz) δ 21.0,
23.3, 28.0, 34.5, 68.5, 115.5, 116.0, 126.0, 126.5, 126.8,
131.9, 135.8, 139.4, 153.0, 157.3, 178.1.
Protein expression and purification
The TRα-LBD and TRβ-LBD constructs were fused in
frame to the C-terminus of a poly-histidine (his) tag into
a pET28a(+) plasmid (Novagen).
hTRα The human TRα1 LBD construct including amino-
acid residues Glu148-Val410 (NCBI protein accession No.
A40917) was expressed in Escherichia coli strain B834
(Novagen). The expression and purification of the GC-1
bound TRα-LBD was accomplished as described in Nunes
et al. [36].
hTRβ The human TRβ1-LBD construct, which includes
amino-acid residues Glu202-Asp461 (NCBI protein acces-
sion No. NP000452), was expressed in E. coli strain
BL21(DE3) (Stratagene). A Luria Broth (LB) starter culture
was inoculated with a single colony of a LB-agar culture
and grown overnight at 37°C. The initial culture was inoc-
ulated at 1% in a major 2× LB culture and grown at 22°C
in kanamycin medium until the A600 nm reached 1.5.
Then 0.5 mM isopropylthio-β-D-galactoside (IPTG) was
added and the culture was incubated for 4–6 hours at
22°C. The induced cultures were harvested by centrifuga-
tion and the pellets were resuspended in 50 mM Tris-HCl,
pH 8.0, 150 mM NaCl, 0.05% Tween 20, 20 mM β-mer-
captoethanol. Phenylmethylsulfonylfluoride (PMSF) and
lysozyme were added to 1 mM and 250 µg/ml, respec-
tively, and the culture was placed on ice for 30 min. The
lysate was sonicated and clarified by centrifugation for 20
minutes at 14.000 rpm in a Sorvall SS34 rotor at 4°C. To
produce the holo protein, GC-1 ligand was added right
after supernatant clarification in a molar excess of 10× and
incubated for 1 hour at 4°C. The supernatant was incu-
bated in batch with 1 ml Talon Superflow Metal Affinity
Resin (Clontech)/liter of culture for 1 hour at 4°C. The
resin was washed with 50 mM Sodium Phosphate, pH
8.0, 300 mM NaCl, 10% glycerol, 0.05% Tween 20, 10
mM β-mercaptoethanol. The bound TRβ protein was
eluted with 50 mM Sodium Phosphate, pH 8.0, 300 mM
NaCl, 10% glycerol, 0.05% Tween 20, 10 mM β-mercap-
toethanol, 500 mM imidazol in a single step. After this
step the protein was loaded into the gel filtration column
HL Superdex 75 26/60 (Amersham Bioscience) equili-
brated with 20 mM HEPES, 1 mM EDTA, 3 mM DTT,
0.01% Tween 20, 200 mM NaCl. The protein recovered
was concentrated by ultra filtration (Amicon Ultra 10
MWCO, Millipore).
Protein content and purity of all chromatographic frac-
tions were checked by Coomassie Blue stained sodium
dodecyl sulfate-polyacrylamide gel elestrophoresis (SDS-
PAGE). The average yield of the protein, with purity
higher than 95%, is 15–20 mg per liter of culture. Protein
concentrations were determined using the Bradford dye
assay (Bio-Rad) and bovine serum albumin as standard.
Crystallization and x-ray analysis
Crystals of the complexes TRα and TRβ were grown by
hanging-drop vapour diffusion. The crystals were grown
at 277 and 291 K by the sparse-matrix method, using the
macromolecular crystallization reagent kits I and II
(Hampton Research). In each trial, a hanging drop of 1–3
µl of protein solution (10 mg/ml in water), containing
GC-1 or T3, was mixed with 1–3 µl of precipitant solution
and equilibrated against a reservoir containing 500 µl of
precipitant solution. For both TRα and TRβ complexes,Page 10 of 13
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tions similar to those reported for human TRβ LBD [16].
Crystals of TRα LBD grew within 12–24 hours from a mix-
ture of the protein construct at 10 mg/ml mixed with the
reservoir solution containing 1.0 M to 1.2 M sodium ace-
tate and 100 mM sodium cacodilate, pH 7.2 in 1:1 pro-
portion. Two crystal forms has been observed in a nearly
identical crystallization conditions: one belonging to the
orthorhombic space group P212121 and another – to a
monoclinic space group C2.
TRβ LBD crystals grew from a 1:1 mixture of protein at the
concentration of 10 mg/ml with the reservoir solution
containing 1.2 M sodium acetate, 200 mM sodium succi-
nate and 100 mM sodium cacodilate, pH 7.5 within 12–
24 hours. The crystals space group was P3121.
X-ray data collection was done with a MAR Research
MAR345dtb image-plate detector mounted on a Rigaku
ultraX 18 rotating anode X-ray generator, equipped with
an OSMIC confocal Max-Flux optics and operated at 50
kV and 100 mA. To prevent radiation damage, crystals
were briefly soaked in a cryoprotectant solution contain-
ing 20% and 15% (v/v) ethylene glycol, respectively for
TRα and TRβ, and rapidly cooled in a gaseous nitrogen
stream (Oxford Cryosystems) at 100 K. In all cases, the
oscillation range was 1°, with exposure times of 15 min
per image. A single data set was collected for each crystal.
The data sets were reduced, merged, integrated and scaled
using the softwares DENZO and SCALEPACK [38]. A sum-
mary of the data processing is given in Table 1.
Structure Determination and Refinement
The structures were determined by molecular replacement
using the software AMORE and the TRβ LBD+T3 (PDB
code: 1BSX) structure as a model[39]. We have alternately
run cycles of refinement using REFMAC5, and model
building using O and COOT [40-42]. hTRβ electron den-
sity is fragmented in the region between residues Ala253
and Lys263, which could not be modelled. For hTRα+GC-
1 complex in P212121 (the first crystal form) the final
model consists of residues 144–410 plus 477 water mole-
cules and a molecule of GC-1, while the hTRα+GC-1
structure in C2 (the second crystal form), the model con-
sists of residues 144–405 and one GC-1 molecule.
Because of the higher resolution and better quality of the
X-ray data, we based our structural comparison mostly on
the hTRα model refine in the first crystal form, unless
explicitly stated. hTRβ+GC1 complex contains residues
201–252 and 264–460, 36 waters and one ligand mole-
cule. hTRα+T3 model contains residues 142–408, 427
water molecules and a molecule of T3, and hTRβ+T3
structure consists of residues 202–252 and 264–460, 128
water molecules and one ligand molecule.
Cell culture, electroporation, and luciferase cell-based 
assays
HeLa cells were cultured in DMEM media, containing
10% fetal bovine serum, 2 mM glutamine, 50 units/ml
penicillin, and 50 µg/ml streptomycin. Cells were col-
lected and resuspended in phosphate-buffered saline con-
taining 0.1% dextrose and 0.01% Ca2+. For each
transfection, 1 µg of GAL•TR expression vector (GAL4
DBD fused to hTRβ 1 LBD) was cotransfected with 4 µg of
the reporter gene contained five GAL binding sites
upstream of the adenovirus E1b minimal promoter linked
to luciferase coding sequence (LUC). Cells were electropo-
rated at 300 mV and 950 microfarads, transferred to fresh
DMEM media, and then distributed in 12-well plates.
After incubation for 20 h at 37°C and 5% CO2, with eth-
anol, or 1 µM T3, or 1 µM GC-1, the cells were collected
and the pellets were solubilized by addition of 150 µl of
100 mM Tris-HCl, pH 7.8 containing 0.1% Triton X-100.
The LUC activity was analyzed by adding 25 µl of luciferin
to 25 µl of the lysate immediately before measurements in
a luminometer (Luciferase Assay System, Promega).
Molecular dynamics simulations
Coordinates for TRa LBD and TRβ LBD structures,
obtained as described above, were used in the molecular
dynamics simulations. Missing residues were modeled,
particularly the O-loop in TRβ structures. The modeling
was performed by finding the lowest energy structure that
contain the missing residues for which the N-terminal and
C-terminal ends fit the restraints of the positions they had
to have in order to be well incorporated into the overall
LBD structure. The complete structures were then solvated
by a water shell of at least 15 Å around the LBD using with
the package Packmol [43]. Sodium and chloride ions were
also added to solvent to keep the overall systems neutral.
No periodic boundary conditions were used. These sol-
vated systems were then minimized by 1000 steps of con-
jugate-gradient minimization as implemented in NAMD
keeping, however, all the protein and ligand atoms, except
the modeled ones, fixed [44]. Subsequently, 100 ps of
thermalization at 298.15 K with velocity scaling at every 1
ps was performed, again keeping all atoms, except the
modeled ones, fixed. Following these first steps of ther-
malization, another 100 ps of simulations were per-
formed with velocity scaling at every 1 ps, but keeping
only the α-carbon atoms of non-modeled residues fixed.
Finally, 100 ps of thermalization with velocity scaling at
every 1 ps were performed without any position restraint.
From this final structure, unrestrained simulations 1 ns
long were performed in the NVE ensemble and the inter-
action energies were computed from these last simula-
tions. The systems were composed by approximately
54,000 atoms each. In all simulations CHARMM parame-
ters were used. Ligand parameters were obtained by group
analogy from the CHARMM set, and their charges werePage 11 of 13
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available in Martínez et al. [21]. In our simulations all Arg,
Lys, Glu and Asp residues were considered charged. The
binding pocket contains three nearby Arg residues which
could eventually be deprotonated due to electrostatic
repulsions involved. The presence of the ligand's carboxy-
late, the basicity, and the proximity to the solvent of these
residues led us to choose to simulate them charged,
although some alternative protonation states cannot be
ruled out. In these and previous simulations such choice
resulted in satisfactory representations of the mobility of
the binding pocket residues [20,21]. The interaction ener-
gies reported are averages obtained from the energies
computed for each individual simulation snapshot con-
sidered as representatives of each binding mode. The
RMSD reported in Figure 4(a) is an indicative only of the
internal flexibility of the Arg residue since it was com-
puted after a rigid-body alignment of this residue to its
conformation in the first frame of the simulations.
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